SUVN L3307032
Alternative Names: SUVN-L3307032Latest Information Update: 08 Dec 2025
At a glance
- Originator Suven Life Sciences
- Class Neuroprotectants; Neuropsychotherapeutics
- Mechanism of Action Muscarinic M4 receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 27 Jul 2025 Pharmacodynamics and adverse event data from a preclinical study in neurological disorders presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)
- 28 Jul 2024 Preclinical trials in Neurological disorders in India (unspecified route)
- 28 Jul 2024 Pharmacodynamics and pharmacokinetics data from a preclinical study in neurological disorders presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)